In 2023, the mortality rate for trachea, bronchus, or lung malignant neoplasms among men in the US was recorded at 40.1 deaths per hundred thousand males. From 2024 to 2028, the forecast suggests a consistent decline. The year-on-year percentage variations are as follows: a 3.4% decrease in 2025, followed by a 3.7% decrease in 2026, and successively, decreases of 3.6% in 2027 and 3.7% in 2028. Over this five-year period, the compound annual growth rate (CAGR) is a decline of approximately 3.7%.
Future trends to watch for include advancements in early detection and treatment methods, shifts in smoking rates, air quality improvements, and healthcare policy changes that could further impact the mortality rates for trachea, bronchus, or lung cancers.
